3
Announcements
Trials
Browse
Landscape
Phase
Phase EARLY_PHASE1
1
Phase 2
1
Phase 1/2
1
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Head & Neck
1
Genitourinary
1
Endocrine
1
CNS
1
Conditions
Wilms Tumor
1
Uveal Melanoma
1
Thyroid Cancer, Papillary
1
Sarcoma, Ewing
1
Sarcoma
1
Salivary Gland Neoplasms
1
Recurrence
1
Neuroblastoma
1
Nephroma, Mesoblastic
1
Neoplasm Metastasis
1
Medulloblastoma
1
Glioma
1
Central Nervous System Neoplasms
1
Brain Neoplasms
1
Interventions
Gemcitabine
15
pembrolizumab
13
Doxorubicin
13
Radiotherapy
12
Docetaxel
9
Nivolumab
8
Filgrastim
7
Cyclophosphamide
7
pazopanib
6
Ifosfamide
6
130-nm albumin-bound paclitaxel
5
Temozolomide
4
Irinotecan
4
Ipilimumab
4
Imatinib Mesylate
4
Albumin-Bound Paclitaxel
4
talimogene laherparepvec
3
surufatinib
3
pegfilgrastim
3
eribulin
3
atezolizumab
3
Vinorelbine
3
Sirolimus
3
Peripheral Blood Stem Cell Transplantation
3
PM 01183
3
Drug Therapy
3
Cisplatin
3
toripalimab
2
spartalizumab
2
selinexor
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Sarcoma
×
entrectinib
×
Clear all
NCT02650401
2026-03-25
STARTRK-NG
Hoffmann-La Roche
Phase 1/2
Active not recruiting
69 enrolled
1 FDA